De-mystifying the ‘Mixifusor’ by Absalom, AR et al.
Title 
De-mystifying the ‘Mixifusor’ 
 
Authors 
Absalom AR,1 Rigby-Jones AE,2 Rushton AR,3 Sneyd JR,4 
 
Author affiliations: 
1 Professor of Anesthesiology, University Medical Center Groningen, University of 
Groningen, Groningen, The Netherlands 
2 Lecturer in Pharmacology (Education), Faculty of Health: Medicine, Dentistry and Human 
Sciences, University of Plymouth, UK 
3 Consultant Anaesthetist, Department of Anaesthesia, University Hospitals Plymouth, 
Plymouth, UK. 
4 Emeritus Professor, Faculty of Health: Medicine, Dentistry and Human Sciences, University 
of Plymouth, UK 
 
Correspondence to:  
Name:   Prof. A. R. Absalom 
Email:   a.r.absalom@umcg.nl 
Address:   Department of Anesthesiology 
University Medical Center Groningen 
Post box 30.001 






Conflict of interest statement: 
ARA: his research group/department received grants and funding from The Medicines 
Company (Parsippany, NJ, USA), Becton Dickinson (Eysins, Switzerland), Dräger (Lübeck, 
Germany), Paion (Aachen, Germany), Rigel (San Francisco, CA, USA); and he has received 
honoraria from The Medicines Company (Parsippany, NJ, USA), Janssen Pharmaceutica NV 
(Beerse, Belgium), Becton Dickinson (Eysins, Switzerland), Paion (Aachen, Germany), Rigel 









Total intravenous anesthesia (TIVA) using a mixture of propofol and remifentanil in 
the same syringe has become an accepted technique in Pediatric Anesthesia. A 
survey by a group of respected UK anesthetists demonstrated a low incidence of 
serious complications, related to the pharmacology and dose of the drugs. However, 
a current guideline for the safe use of TIVA recommends against this practice. 
Pharmaceutical concerns include the physical stability of the emulsion when 
remifentanil is mixed with propofol; changes in drug concentration over time; non-
uniform mixing of propofol and remifentanil; the risk of bacterial contamination; and 
the potential for drug administration errors. 
Propofol and remifentanil have markedly different pharmacokinetic profiles. When 
remifentanil is mixed with propofol and delivered as a target-controlled infusion (TCI) 
of propofol, remifentanil delivery is not target-controlled but passively follows the 
variable infusion rates calculated by the syringe driver to deliver predicted plasma or 
effect-site concentrations of propofol. The pharmacokinetic consequences can be 
illustrated using pharmacokinetic modelling similar to that used in TCI pumps. The 
clinical consequences reflect the dose-dependent pharmacodynamics of remifentanil. 
Increasing the target propofol concentration produces a rapid increase and peak in 
remifentanil concentration that risks apnoea, bradycardia and hypotension, especially 
with higher concentrations of remifentanil. The faster decline in remifentanil 
concentration with falling propofol concentrations risks inadequate narcosis and 
unwanted responses to surgical stimuli. Remifentanil delivery is inflexible and dosing 
cannot be adjusted to the clinical need and responses of individual patients. 
The medicolegal considerations are stark. In UK and EU Law, mixing propofol and 
remifentanil creates a new, unlicensed drug and the person mixing takes on the 
responsibilities of manufacturer. If a patient receiving anesthesia in the form of a 
mixed propofol-remifentanil infusion suffered a critical incident or actual harm, the 
clinician’s practice may come under scrutiny and criticism, potentially involving a legal 
challenge and the Medical Regulator. 
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Older anaesthetists may remember the crunch of precipitating thiopental caused by 
injecting succinylcholine into an un-flushed cannula. Trial and error (lots of errors…) showed 
that precipitation may follow in any number of unlicensed drug mixtures with succeeding 
generations repeating the mistakes of their predecessors. 1,2 Naïvely, anaesthetists may 
assume that the absence of crystals or of any other changes visible to the naked eye, implies 
compatibility but this is not necessarily the case. Ever since it first became available for use 
in clinical practise, anaesthetists have experimented with the addition of diluents and other 
drugs to the propofol formulation. As propofol is presented as a sterile oil in water emulsion, 
the addition of diluents and other drugs poses several problems.  The opacity of the propofol 
emulsion likely conceals any evidence of crystallised drug, and important changes in the lipid 
emulsion characteristics are not visible to the naked eye.  
The most common additive is lidocaine, which reduces pain on injection. 3,4 
Anaesthetists have also added other drugs such as alfentanil or ketamine to propofol, 
because they wish to infuse propofol and the added drug, using a single infusion pump.5-7  
Reasons for using a single pump to infuse two or more drugs range from convenience to a 
lack of resources.  
Total intravenous anesthesia (TIVA) is growing in popularity among pediatric 
anesthetists, often using a mixture of propofol and remifentanil.8 There are several reasons 
why pediatric anaesthetists might be tempted to use this technique. A second infusion pump 
is not always readily available, even in high resource countries, and administration of 
remifentanil from a separate syringe and line increases cost. Pediatric surgery operating 
schedules commonly list several short duration procedures in quick succession, and mixing 
of two drugs in one syringe saves (a small amount of) time. Finally, in small children, it is 
desirable to limit administered fluid volumes, and mixing remifentanil in the propofol 
emulsion reduces the volume of carrier fluid.  
A recent guideline for safe use of total intravenous anaesthesia (TIVA) noted the 
increasing prevalence of mixing of drugs among pediatric anaesthetists, but recommended 
against this practise, particularly when propofol is administered by target-controlled infusion 
(TCI).9 The reasons for caution quoted in the guideline are largely consistent with those 
mentioned in a previous editorial on mixing,10 which center mostly on medio-legal and 
safety concerns. In an attempt to demonstrate the safety of mixing propofol and 
remifentanil, a group of respected UK pediatric anaesthetists performed a service evaluation 
of the safety and efficacy of this technique in almost 900 patients, and presented their 
findings in this journal.11  
Bagshaw and colleagues prospectively collected data from 880 patients, the majority 
of whom were healthy (88% ASA 1-2) and younger than 11 years of age (76%), undergoing a 
wide range of procedures (16 specialties in total). In the majority of cases (79%) the 
remifentanil concentration was 5 mcg/ml in the 1% propofol emulsion (or its equivalent 
mixture, remifentanil 10 mcg/ml in 2% propofol) , but there were also instances when 2.5, 
10 and 20 mcg/ml (or equivalent) were used. In brief, there were 224 complications during 
159 anaesthetics. The majority were minor and expected, such as movement or coughing, 
whereas the incidence of events that were serious, related to the pharmacology of the drugs 
but unexpected and requiring intervention, was only 1.7%. With a sample size of 873 
patients, the 95% confidence interval for this proportion is approximately 1 – 2.8%. 
Complications were more likely to occur when the remifentanil concentration in the syringe 
was ≥ 10 mcg/ml.  
Does this result show that it is acceptable for you to try out this technique in your 
hospital? A clinical practise is traditionally regarded as acceptable and defensible if a body of 
respected colleagues uses it, and this is certainly the case here. Do these data prove that the 
technique is safe? This is a tough question to answer. The confidence interval mentioned 
above certainly falls well below the published incidence of severe complications found in the 
APRICOT study (3.3% in the UK, 5.2% across all involved countries).12  On other hand, safety 
is usually only regarded as proven once a drug or technique has been studied in thousands 
of patients, and under similar conditions. The investigators are all highly experienced 
experts, and they present the results of an observational study in what is essentially a 
convenience sample. If you are considering trying this practise in your own hospital, then it 
would be worthwhile spending some time in the company of an expert to learn the 
technique.  
Moreover, this study simply looked at the incidence of clinical adverse events. Issues 
that the study did not address, but which should be borne in mind include: physicochemical 
stability and compatibility of the mixture, other safety aspects including bacterial 
contamination and drug error, differences in pharmacokinetics of the two drugs which can 
cause specific problems when infusion rates are high or low, and finally medicolegal matters. 
Some of these have been discussed previously,10 but we feel that their importance is 
sufficient to warrant a reprise.  
 
Properties of emulsions and what mixing will do to them 
Ordinarily an oil in water emulsion is in a dynamic state. Droplets coalesce producing fewer 
but larger ones. Ultimately visible “creaming” may occur. Historically this was visible in glass 
bottles of milk where over time fatty droplets coalesced and then floated to the top of the 
aqueous component, forming a layer of cream. 
The original commercial propofol formulation, Diprivan ® (AstraZeneca, Macclesfield 
UK), contains propofol emulsified in 10% Intralipid ® (Kabi, Munich, Germany), which 
contains soya oil (100 mg/ml), egg yolk lecithin (12 mg/ml), and glycerol (22.5 mg/ml). This 
emulsion is subjected to homogenisation producing droplets of 150-300 nm diameter which 
are stabilised and emulsified by the egg yolk lecithin.13   In addition to providing a physical-
chemical barrier at the surface of each droplet, the 3 long-chain acids of egg lecithin support 
a stable negative electrostatic charge, the zeta potential which causes droplets to repel each 
other thereby maintaining their dispersal and subsequently the stability of the emulsion.  
Addition of an ionised drug such as lidocaine hydrochloride to a propofol emulsion provides 
a charge carrier allowing dispersal of the zeta potential, increasing droplet size and 
potentially precipitating creaming. Thus the datasheet (summary of product characteristics, 
SPC) for propofol specifies that propofol emulsion diluted with 5% dextrose solution 
(uncharged) or supplemented by alfentanil (mostly unionised) may be considered stable 
over a 6 hour period whereas propofol with added lidocaine (mostly ionised) must be used 
immediately.14 Admixture of remifentanil is not mentioned. 
 
(In)stability of remifentanil and propofol in a mixture 
Stewart and colleagues studied the stability of propofol and remifentanil concentrations 
when the drugs are mixed, for 36 hours.15 Using Diprivan 1% they prepared mixtures 
containing 5mcg/ml and 50 mcg/ml, in standard plastic syringes, and in PVC bags. For each 
mixture control solutions were also prepared – i.e. remifentanil only (5mcg/ml and 50 
mcg/ml solutions) and propofol only (10mg/ml) – in plastic syringes and PVC bags. In the 
5mcg/ml admixtures in plastic syringes and PVC bags, remifentanil concentrations decreased 
significantly over time (by 8 and 12% respectively within the first hour), whereas in the 50 
mcg/ml admixtures the remifentanil concentrations remained stable. The control solutions 
all remained stable, except for propofol in PVC bags, whereas the propofol concentrations 
declined slowly over time, presumably because of interaction between the propofol and the 
PVC of the bag.  
In the Bagshaw study 11 the majority of clinicians used admixtures with 5 mcg/ml of 
remifentanil, a concentration in which the remifentanil concentration declines over time, but 
which is associated with a lower incidence of adverse events. Given the fact that the median 
duration of administration was 32 minutes, the decline in remifentanil concentration over 
this time is unlikely to have been clinically significant.  
 
Layering issues / Migration of remifentanil within mixtures 
When two drugs are mixed and then infused, the infusion rates of each drug will only be and 
remain consistent with expectations if each drug mixes uniformly throughout the mixture. 
O’Connor found that this is not the case for propofol and remifentanil.16  They added 
remifentanil to propofol 1% in a vertically mounted syringe to produce mixtures containing 
remifentanil 25, 50 and 100 mcg/ml. Immediately after mixing, and for the duration of their 
experiment (300 minutes), the remifentanil concentrations were significantly higher in the 
uppermost portions of the mixture. For propofol the gradient was in the opposite direction. 
This effect was most pronounced for the 25 mcg/ml mixture. Ten minutes after mixing the 
drugs, the concentrations at the top and bottom of the mixture were: 16 and 4 mcg/ml for 
remifentanil, and 5.3 and 8.6 mg/ml for propofol respectively. Their results showed that in 
addition to the large gradients, the concentrations of both drugs were significantly lower 
than expected. 
In the Bagshaw study,11  anesthetists used a TCI pump to administer the mixture, and 
on all current TCI pumps the syringe is mounted horizontally. Although it is likely that the 
layering mentioned above is less of a problem with a horizontally mounted syringe, this has 
not been evaluated in a published study.  
 
Bacterial contamination 
Propofol emulsions are sterile but strongly support bacterial growth at room temperature. In 
most countries the emulsion does not contain an antiseptic (the USA in an exception). The 
triad of inadvertent contamination (during preparation), a period of incubation and 
subsequent administration, led to very serious and sometimes catastrophic clusters of 
infections in the USA.17,18   Since 1996, propofol formulations sold in the USA have contained 
either EDTA or sodium metabisulphite (which apparently do not alter the safety or stability 
of the emulsion).18 European anesthetists rely on hand hygiene and aseptic technique. 
When remifentanil is added to propofol, it must first be dissolved, as it is presented 
as a powder, and this step and the subsequent addition to the propofol present 
opportunities for contamination. 
 
Lack of standardisation; risk of drug errors 
Propofol/opioid mixtures are visibly indistinguishable from the unadulterated injectate 
thereby generating opportunities for drug administration errors. Although strict regulations 
require the proper labelling of drugs prepared in operating theatres, these are not 
universally followed. Further, the additive increases the net volume of the mixture thereby 
decreasing the concentration of propofol in the resulting mixture. Whilst the dilution caused 
to a 47.5ml syringe of 1% propofol injection by the addition of remifentanil 250 mcg in 2.5 
ml (made by diluting remifentanil 1mg to 10ml) is probably insignificant – the resultant 
propofol concentration is 0.95% instead of 1.0% - this effect may become relevant if larger 
volumes of injectate are added to propofol solutions.  
 
Legal considerations 
In the UK, the Medicines and Healthcare products Regulatory Agency clearly describes the 
legal position of mixing of drugs as follows:  
 
“Under current UK and European legislation, except in very restricted circumstances, 
mixing drugs together, where one is not a vehicle for the administration of the other, 
creates an unlicensed medicine. The person undertaking this preparation, unless an 
exemption applies, must hold a manufacturer’s licence. ”19 
 
The above implies, in theory at least, that the mixer becomes the manufacturer (of the 
mixture) and is therefore legally liable for the consequences of its administration. This is a 
daunting prospect, albeit a theoretical one. Furthermore, as these mixtures constitute 
unlicensed medicines, and/or off-label use of licensed medicines, this adds to the 
responsibilities of the clinician. Not only does the UK General Medical Council advise doctors 
against using drugs in a non-standard and unapproved manner,  it also specifically advises 
clinicians about the additional requirements for documentation, and consent.20  
 
Pharmacokinetic incompatibility  
The pharmacokinetics of propofol and remifentanil can be described by multi-compartment 
mammillary models.21 Although these models contain some assumptions which are 
demonstrably invalid (for example that mixing within the central compartment is 
instantaneous after administration), George Box’s remark that "all models are wrong, but 
some are useful" certainly applies.22 As these models are ubiquitous in anaesthesia teaching 
and research and are widely deployed in TCI systems,23 we can turn to them to describe the 
likely consequences of co-administering propofol and remifentanil, whose pharmacokinetics 
and pharmacodynamics differ. In the Bagshaw study,11 the responsible anesthetists most 
commonly administered a mixture containing 5 mcg/ml of remifentanil in propofol 1% using 
a TCI pump programmed with the Paedfusor 24 pharmacokinetic model for propofol, with a 
median starting target concentration of 4 mcg/ml and a median end concentration of  2.9 
mcg/ml .  
Figure 1 near here 
Figures 1 to 3 represent a simulated infusions of this mix. To simplify the calculations we 
have assumed a propofol concentration of 10mg/mL (i.e. 1%) and a remifentanil 
concentration of 5 mcg/mL in the mix. For each figure we first used Stanpump software i to 
calculate the infusion rates required for the simulated plasma target propofol concentration 
profile, with the Paedfusor model parameters for a 10 year old male, weight 32kg and height 
140cm.  For illustration purposes we also estimated the effect-site propofol concentration 
using a ke0 of 0.26/min.25  We then programmed Stanpump with the Eleveld PK/PD model 
parameters for remifentanil for this child,26 to estimate the resulting estimated remifentanil 
plasma and effect-site concentrations arising. Figure 1 shows that when the infusion is 
started at a target concentration of 4 mcg/mL, there is a rapid but temporary rise in 
remifentanil plasma and effect-site concentrations. The peak effect-site concentration is of 
the order of 5 ng/ml but thereafter it will plateau at around 2 ng/ml. Whereas 5 ng/ml is an 
appropriate concentration during painful procedures (such as laryngoscopy) the subsequent 
plateau concentration is at a level at which most patients will not breathe spontaneously, 
but will still move in response to painful stimuli. At present, clinically available TCI pumps do 
not allow effect-site controlled TCI with the Paedfusor and Kataria models. Should this mode 
become available in the future, then clinicians should remember that the initial bolus is 
bigger with effect-site targeting than with plasma targeting. In this case, if a TCI pump is 
used to administer an effect-site targeted infusion of a propofol remifentanil mixture, the 
peak remifentanil concentrations will be substantially higher than 5 ng/ml, particularly if the 
TCI pump is programmed with a slow (low value) ke0. 21   
Figure 2 near here 
If the propofol target concentration is initially 4 mcg/mL but is decreased to 2.9 mcg/mL 
after 10 minutes (Figure 2) causing the infusion of the mixture to stop temporarily, the faster 
kinetics of remifentanil dictate that the remifentanil concentrations will fall proportionately 
more than the propofol concentration. In fact, the simulation shows that the estimated 
effect-site remifentanil concentrations will fall to around 1 ng/ml a level that is insufficient 
to inhibit movement responses to pain. In essence the simulation shows much less stable 
remifentanil plasma and effect-site concentrations than propofol concentrations, with 
declines to inadequate remifentanil concentrations.  
Since the kinetics of remifentanil are linear, the achieved plasma and effect-site 
concentrations can be extrapolated from the above simulations. Mixtures containing less 
remifentanil will likely result in inadequate plasma and effect-site concentrations, and this 
will be exacerbated by the instability of remifentanil over time in mixtures containing low 
remifentanil concentrations. On the other hand, more concentrated mixtures will result in 
very high peak effect-site remifentanil concentrations (>= 10  ng/ml) at which adverse 
effects are expected (bradycardia and hypotension) and plateau and nadir concentrations at 
which apnoea will be invariable.  
 
Feedback from clinicians and simulation suggest that the impact of the transient 
remifentanil overdosage at the start of TCI may be attenuated by staging the approach to 
the initial TCI target rather than achieving it in a single step (figure 3). 
Figure 3 near here 
 
Conclusion 
Although pediatric anesthetists who administer propofol-remifentanil mixtures are probably 
in good company, they should remember that this technique has several dangers, theoretical 
or otherwise, as described above. Clinicians should be aware that if they practise this 
technique, and a patient under their care suffers a critical incident, it is likely that their 
practise will come under close scrutiny. While they could offer as a defence the fact that 
there is a body of reasonable and experienced clinicians who practise this technique, it is 
unlikely that they will find support from health and regulatory bodies (such as the MHRA and 
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FIGURES   
  
Figure 1. Simulated Target Controlled Infusion of propofol (target plasma concentration 
4mcg/mL for 20 min) for a 10 year old male, weight 32kg and height 140cm using 
Stanpump software. Remifentanil has been added to the propofol to yield a 
concentration of 5mcg/ml. Predicted plasma propofol concentration (heavy solid line) 
and effect site concentration (heavy dashed line). Predicted plasma remifentanil 
concentration (thin solid line) and effect site concentration (thin dashed line). The 
Paedfusor and Eleveld pharmacokinetic sets were used for propofol and remifentanil 
respectively. Predicted effect site remifentanil concentration overshoots when the 




Figure 2. Simulated Target Controlled Infusion of propofol (target plasma concentration 
4mcg/mL for 10 min then 2.9mcg/ml for 10min) for a 10 year old male, weight 32kg and 
height 140cm using Stanpump software. Remifentanil has been added to the propofol to 
yield a concentration of 5mcg/ml. Predicted plasma propofol concentration (heavy solid 
line) and effect site concentration (heavy dashed line). Predicted plasma remifentanil 
concentration (thin solid line) and effect site concentration (thin dashed line). The 
Paedfusor and Eleveld kinetic sets were used for propofol and remifentanil respectively. 
Predicted effect site remifentanil concentration overshoots when the infusion is started 
and undershoots when the target concentration is decreased at 10min. 
 
 
Figure 3. Simulated Target Controlled Infusion of propofol (target plasma concentration 
2mcg/mL for 2 min, thereafter 4mcg/ml) for a 10 year old male, weight 32kg and height 
140cm using Stanpump software. Remifentanil has been added to the propofol to yield a 
concentration of 5mcg/ml. Predicted plasma propofol concentration (heavy solid line) 
and effect site concentration (heavy dashed line). Predicted plasma remifentanil 
concentration (thin solid line) and effect site concentration (thin dashed line). The 
Paedfusor and Eleveld pharmacokinetic sets were used for propofol and remifentanil 
respectively. Staging the approach to the initial target plasma concentration of propofol 






i Freely available from the author at http://opentci.org/code/stanpump (accessed 22 September 2020) 
